Spots Global Cancer Trial Database for A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Official Title: A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Study ID: NCT05180799
Study Description
Brief Summary: The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Detailed Description: This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3071 in combination with a PD-1 blocking antibody, nivolumab, in patients with advanced solid tumors.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinic and Research Institute, Los Angeles, California, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Piedmont West, Atlanta, Georgia, United States
Horizon Oncology Research, LLC, Lafayette, Indiana, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Providence Cancer Institute, Portland, Oregon, United States
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
Cancer Care Foundation, Miranda, New South Wales, Australia
Cancer Research South Australia, Adelaide, South Australia, Australia
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
